Note: Descriptions are shown in the official language in which they were submitted.
WO9l/12023 PCT/US91/00971
~7~927
-1 -
~YBRID REAGENTS CAPABLE OF SELECTIVELY
RELEASING MOLECULES INTO CELLS
Back~round of the Inven~ion
Hybrid antibodies are antibodies or a~gregates
05 of antlbodies which arei specific for ~wo d~fferent
antl~ens. Hybrid antibodies can co~prise a -~ingle
antiboty or fragment having a bispecific antigen
binding region (two different Yariabla regions) or
ag~regates of two or ~ore antibodies of different
10 speciflcie:ie5. -- - -
Different ~ethods of preparing hybrld anti~bodies have b~en reported. Auditore-Hargre~ves
~eaches proc~isses for preparing hybrid antibodies by
generating "half molecules n from two parent an~i-
bodies and subsequently associating different halfmolecules. See U.S. Patents 4,470,925 (1984) and
4,479,895 (1984). Uslng this process, various
hybrid antibodles ~ere prepared with speclficities
for horseradish peroxidase, glucose oxidase and
theophylline.
Reading describes production of antibodies
having blnding pac~ficit~es for two desired
anti~ens using a quadroma ccll or a trioma cell.
See U.S. Patant 4,474,893 (1984). The quatroma cell
25 i8 the iui~ion product of two different hybrido~a
cells, a~ch of which produce an antibody with a
d~fforent specificity. A trioma cell is the fusion
product of a hybridoma and a lymphocyte which
.
produces ~ntiboties with two differe~t binding
specificities.
':
.
.
' . . ' . : . . . . .. . . . ,. ., ~ ~ . ' , . :
WO91/12023 PCT/US91/~71
Segal et al. describe earget specific cross-
linked heterDantibodies which are used as cytotoxic
agents in U.S. Patent 4,676,980 (1987). Staerz et
al. (1986), PNAS, 83:1453-1457, teach the use of a
05 hybrid antibody that can focus effective T cell
activ~ty and Milstein et al. (1983), Nature,
305:537-539, describe the use of hybrid antibodies
in i~munohistochemistry.
Raso et al., Cancer Research, 41:2073-2078
(1981) disclose the use of hybrid antibodies with
dual specificity for the plant ~oxin, ricin, and
immunoglobulin-bearing target cells. The hybrid
antibodies were constructed in vitro and the
attachment of the hybrid antibody-ricin complex to
the human target cells was observed using fluor&s-
cein labeled antibodies. Upon binding, the human
tar~et cells were selectively killed by the
hybrid-delive~ed toxin.
Prior to the use of hybrid antibodies, chemical
crossIinking or nonspecific absorption methods were
used to couple~drugs and/or toxins to antibody
carriers. These agents possess certain limitations
due to the nature of the linkage. The linkage may
alter the drug or toxin such that the therapeutic or
toxic activity is reduced. Moreover, cleavage o
the covalent bond may be rate-limiting for the
action of toxin inside the cell.
The use o hybrid antibodles obviated some of
the problems encountered with chemical crosslinking
or non-specific absorption methods; however, new
problems were created. Because the drug or toxin is
WO91/12~23 PCT/US91/0~971
2~7 .~)927
bound to an an~ibody, the therapeutic or toxic
activity is generally inhibited. Hybrit antibody-
deliYered toxins or drugs are inactive when bound to
the antibody and only become 2ctive upon releAse.
05 However, the hybrid antibodies currently available
have no mechanism for releasing the toxin or drug
from the respective antibody bindin~ region when the
hybrid antibody reaches the target site or the
interior of the cell. Instead, they rely on
fortuitous dissociation. As a result,-relatively-
large quanti~ies of hybrit antibodies containing
drugs or toxins must be administered, because only a
small ~mount of the drug or toxin will dissociate
and become active.
Summary-o~-th~-lnve-tion
This invention pertains to hybrid rea~ents
comprising a first portion having an affinity for a
cellular target (e.g., antibody, virus, ligand,
receptor or molecule) and a second portion ha~ing an
affinity for a bioactive molecule (e.g., a toxin,
drug, enzyme or ~etal). The hybrid reagents can be
administered in vivo where they blnd to the external
surface of a cell. Once bound to the cell,
receptor-mediated endocytosis serves to pinch
off the surface of the cell forming an endosome,
which h~s a low0r pH thsn either outside or
within the rest of the cell. In response to the
pH chan~e inside the endosome, the hybrid
reagents o~ the present inven~ion selectively
W~91/12023 PCT/US~I/00971
release the bioactiYe molecule. Once released, the
bioacti~e molecule is free to perform its function.
Therefore, a major advantage of hybrid reagents
of this invention o~er currently svailable hybrid
05 antibodies, which rely on fortuito~s dissociation of
bioacti~e mol~cules, is that ~ess of the hybrid and
bioactive molecule need to be ~dministered to
produce the desired diagnostic or therapeutic
effect.
The present in~ention also encompasses.pharma-
ceutical compositions comprising said hybrid
reagents having a bioactive molecule bound thereto,
methods of i~munotherapy and a method for selecting
antibodies or fragments thereof capable of binding a
bioactive molecule at one pH and releasing that
molecule in response to a change in pH~
Brief Description of the Fi~ures
Figure 1 is a sche~atic dia~ram depicting the
delivery to a cell of a bioactive molecule fro~ a
hybrid reagent by receptor media~ed endocytosis and
release of the bioactive molecule in rasponse to the
lower pH found within a cellular endosome.
Figure 2 is a graph plotting the percent
dissoclation ~i.e., release) of monoclonal antibody
6B3 from diptheria toxin o~er 100 minutes time at a
pH of 4.5 and temperatures of 22C and 37C.
Figurs 3 is a graph plotting the percent
dissociation of monoclonal antibody 6B3 from
dip~heria toxin over 30 minutes time at pH 5.0 and
pH 4.5 at 37C.
' ~ "
WO91/12023 PCT/US91/~0971
2~
Figure 4 is a graph plotting the percent
dissociation of monoclonal antibodies 5A7 and lF3
from diphtheria toxin over 60 minutes time at pH 5.0
at 37-C.
05 Figure 5 is a graph plotting the pe~cent
incorpora~ion of 3H leucine over 180 minutes time as
a measure of protein synthesis inactivation by
native diphtheria toxin and hybr$d-delivered CRM107
in H-meso cells.
....
Figure 6 is a graph pIotting~the toxicity dose- -
response curve for hybrids and conjugates incubated
for 16 hrs. with transferrin receptor posi~ive CEM
cells.
Figure 7 is a graph pl~tting the toxicity
dose-response curve ~or HIV and transferrin receptor
directed hybrids on HIV-infected 8E5 cells.
Detailed Descri~tion of the_Inve_tion
The hybrid reagents of this invention comprise
a first portion having an affinity for a cellular
20 target and a second portion h2ving an affinity for a .
bioactive molecule te.g., a toxin, drug, metal or an
enzyme). The hybrid reagents can be administered in
v$vo where they bind to the extarnal surface of a
cel}. Once bound to tbe cell, receptor-mediated
endocytosis serves to pinch off the surface of the
cell forming an endosome, which has a lowar pH than
either outside or within the rest of the cell. In
,:
response to the change in pH within the endosome,
''.
.
':
. ~
.:
. ''
W~91~12023 PCT/US91/00971
6-
the hybrid reagents selecti~ely release the
bioacti~e molecule. The first portion of the hybrid
can be, for example, a ligand (e.g., transport
proteins such as trAnsferrin, interleukin-2, LDL), a
05 ~rowth factor ~e.g., EGF, PDGF), an antibody, a
hormone, a receptor molecule (e.g., recombinant
CD4), a virus, or a fragment thereof and the second
portion is an antibody or an antibody fragment.
The first portion of the hybrid reagent has an
~ 10 affinity for~a cellu}ar target, such as--an-antigenic
or receptor site on the surface or inside a cell
(i.e., a cell surface antigen or cell surface
receptor). Examples of cellular targets are Ig,
common acute lymphoblastic leukemia antigen (CALLA),
Bl, gp26, Ia, transferrin receptor, EBV transforma-
tion antigen and the receptors for ligands such as
interleukin-2, MSH, insulin, thyroglobulin, LHRH and
NGF. Viral proteins on the surfsce of infected
cells (e.g., HIV-infected T-lymphocyte), can also
serve as targetc for antibody and receptor guided
hybrid reagents.
The second portion of the hybrid reagent is an
antibody or antibody fragment that has an affinity
for a bioactive molecule at one pH snd releases the
bioactive molecule in response to a change ln pH.
This bonding and relea~e may be due to a number of
mechanisms, For exa~ple, the second portion of the
hybrid reagent may ha~e an a~finity for a bioacti~e
molecule tha~ undergoes a conformational change in
rasponse to a change in pH. Such molecules can be
identified by using physical or other methods known
WO9~/12023 PCTtUS91/00971
2~7a~27
-7-
in the art (e.g., circular dichroism, fluorescencs).
As another example, the second portion of the hybrid
reagen~ may ionically bond to a bioac~i~e molecule
ae one pH and the ionlc bond may break in response
05 to a change in pH.
A method for isolating anti~odies that
tissociate from molecules in response to a change in
pH is described in de~ail in Example 1. In general,
antibodies agains~ a bioactive molecule are prepared
using known techniques. Clone supernatants are-then -
a-sayed for the ability to bind t~e molecule at the
first selected pH. Clones testing positive for
binding ability are screened to isolate those that
release the molecule at a second seleceed pH. For
example, antibodies that bind a bioactive molecùle
at physiologic pH (pH about 6.5 to 7.5) can be
tested to isolate those clones that release the ;:
molecules at acidic pH (pH less than 6.5).
Examples of bioactive molecules are plan~ or
bacterial toxins, drugs, enzymes and metals.
Exsmples of useful toxins are diphtheria ~oxin,
pseudomonas exotoxin, ricin, pokeweed antiviral
pep~ide 5PAP), and tricathecum. The toxins can also
be gsnetically or chemically altered or mutated such
lS CRM107 (Laird J. Virol., 19:220-227 (1976)) ant
HA48DT and HA51DT (Myers et al., J. Biol. Chem.,
263:17122 17127 (1988)). Drugs which can be used
in the invention are ~or example, interferon,
insulin, ant methotrexate. Examples of metals which
can be used in the invention are radiometals (e.g.,
Tc-99m, In-lll, Cu-67, Pd-109, Pd-103, Re-188,
. .
' , '; ~;:
.
.
W091/12023 PCT/US91/00971
t^'~
--8-
Au-198, Au-199, Ru-97, H~-197, Ag-lll, Bi-212,
Os-l91 and Pb-203) and non-radioactive me~als (e.g.,
zinc).
Figure 1 illustrates receptor-mediated
05 endocytosis of a hybrid reagent-~olçcule complex.
The first portion of the hybrid reagent binds to the
external surface of the cell, which becomes pinched
off to form an endosome. Endosomes have a pH lower
than (e.g., pH about 4.5-5.5) the pH either outside
or within the rest of the cell (e.g.,~pH about
6.5-7.5) (Geisow, M.L. and W.H. Evans, Ex~. Cell
Res., 150:36-46 (1984)). Therefore, by using a
hybrid rea8ent in which the first por~ion has an
affini~y for a cell surface component and the second
portion h~s an affinity for a bioacti~e molecule at
physiologic pH and dissociates from the bioactive
molecule in response to acidic pH, a ~olecule can be
delivered into a cell and released within acidic
compart~ents of cells, such as cell endosomes.
The hybrid reagen~s can be produced by f oining
~ogether the first and second portions ~sing known
techniques (e.g., chemical coupling, cell f~sion, or
gene~ic engineering techniques). The hybrid
reagents are preferably made by che~ically coupling
the two portion5 togcther. For example, a disulfide
linkage using N-succinimidyl-3-(2-pyridyldithio)
propionate (SPDP) as the crosslinking agent can be
used ~Raso et al., NATO Qdvanced Studies Institute,
82:119-138 (1984)). Both portions become sparingly
substituted with pyridyldisulfide groups whlch are
reduced to thiols on one of the portions. Upon
W~31/12023 PCT/US91/~0971
2 ~ 7 ~ ~ 2 .i
g
mixing of the two portions, the free thiols on one
of the portions readily reacts wlth the unreduced
groups on the second portion and form disulfide
linkages. The resulting hybrids can then be
05 purifled using gel iltxation.
Uhen the first and second portions of the
hybrid reagent are both antibodies, two whole
parental an~ibodies may be joined together to
produce the hybrid reagent ~i.e., hybrid antibody).
A variety of crosslinkin~ agents, such as protein A,
caxbodiimide, and N-succinimidyl-3-(2-pyridyldithio)
propionate (SPDP) can be used to link the whole
parental antibodies ~Kranz et al., Proc. Natl. Acad.
Sci. USA, 78:587 (1981); U.S. Patent 4,474,893)).
The hybrid antibodies can also be produced by
chemically ~oining parental antibody fragments
containing a sufficient portion of the anti~en
binding re~ion to allow the fragment to bind to its
,respective antigen (Nisonoff et al., Arch. Blochem.
Biophys., 93:460-467 (1961) and Raso et al., Cancer
Research, 41:2073 2078 (1981)). The two types of
paren~al antib~dies (i.e., one type will become the
first portion of the hybrid antibody and the other
type will become the second portion) can then be
separately digested with pepsin. Bivalent F(ab')2
molecules are obtained after a separation s~ep such
as chromatography. Equal amounts of the 2F(ab')2
types can then be mixed and after reducin~ their
inter~heavy chain disulfide linkages, the resulting
Fab' fra~ments are allowed to randomly reassemble
i~o F(ab')2 dimers wi~h dual speciflcity. The dual
~ '
'
; ~
WO~1/12023 PCT/U591/00971
'9~
- 10-
specificities of the hybrid product can be verified
using cell-based and solid phase assays which use
radioactive or fluorescent probes (Raso, V.,
Immunol._Re~iews, 62:93-117 (1982)).
05 Alternatively, the intrinsic disulfide links of
the F(ab')2 molecules can be reduced to thiols and
the vicinal thiols genera~ed can be stabilized
(e.~., with sodium arsenite). Ellman's reagent can
be used to activate the vicinal thiols on one type
of ~he Fab' fragments. Upon mixture of the reduced~~~~ ~~ ~~
Fab' fragment with an activated Fab' fragment, an
exclusively bi^sperific hybrid will be for~ed
(Brennan, M., et al., Science, 228:81-83 (1985)).
The hybrid antibodies can also be prDduced
using cell fusion techniques as described in U.S.
Patent 4,474,893, to Reading. In this technique,
hybridoma cells which secrete the parental anti-
bodies are fu~ed together to form quadroma or trioma
cells. These quadroma and trioma cells secrete
bi-specific antibodies possessing the antigen
binding regions of both parental antibodies.
In addition, the hybrid antibodies can be
produced using genetic engineering techniques. In
these procedures, DNA enooding the heavy and light
chain variable regions of each of the parentsl
antibodies are introduced into an appropriate host
cell, preferably A lymphoid cell (e.g., a myeloma
cell). The transfor~ed cell can then synthesize,
assemble and secrete the hybrid antibody.
The parental antibodies used to produce the
hybrit antibody can be selected from those presently
-:
~; .
,
: .
W~91/12023 PCT/U~91/0~971
~ ~ 7 `j 9 2 r~
-11-
available or can be specially prepared. The
parental antibodies can be obtained using conven-
tional monoclonal antibody methodolo~y, (e.g., the
standard so~atic cell hybridizstion techniques of
05 Kohler and Milstein, Nature, 256:495 (1975)).
Suitable antibodies which are specific towards
tu~or associated anti~ens and are therefore
appropriate to comprise the first portion of ~he
hybrid reagent, are for example, 7D3, directed
agalnst the human transferrin receptor, (Griffin et
al., Cancer Res., 47:4266 (1987)); Cl9, direct~d
against the carcinoembryonic antigen, (Gri~fin et
al., J. Biol es~ Modif., 1:194 (1982)); 260F9,
directed againse a breast cancer antigen, (B~orn et
al., C_ncer_Res., 45:1214 (1985)); 96.5 directed
against a melanoma associated antigen, (Casellas et
al., In. J. Cancer, 30:437 (1982)); 45-2D9, directed
against an oncogene product, (Roth et al., J.
Immunol., 136:2305 (1986)) and J-5, directed against
the common acute lyphoblastic leukemia antigen,
(R~so et al., Cancer Res., 42:457 (1982)).
Suitable antibodies which are specific towards
di~theria toxin and are capable of releasing the
toxin in response to a change in pH from physiologic
to acidic, are D5E8, DlF3, D3El, D6B3, D5D5, DlD5,
D5F5 and D4B7. These antibodies are therefore
appropriate to comprise the second portion of the
hybrid resgent.`
The hybrid rea~ents described herein can be
used diagnostically. For example, hybrid molecules
co~prisin~ a first portion which has an affinity for
W091/12023 PCT/US9ltO~971
q,~
-l2-
a tumor cell and a second portion which has an
affinity for a radiometal can be used to deposit
radiometal within tumor cells and thereby obtain a
scintographic image of the tumor.
05 Hybrid reagents of this invention can also be
used therapeutically. For example, hybrid molecules
comprising a first portion ha~i~g an affinity for a
~iral-associated antigen (e.g., an HIV antigen) or a
viral-associated receptor and a second portion
10 ha~ing an-affini~y for a bioactive molecule, can be- - -
used therapeutically to kill or otherwise modify
virus infected cells. Similarly, hybrid molecules
comprising a flrst portion having an affinity for a
tumor ~ssociated antigen or a tumor-associated
receptor ~nd a second portion having an affinity ~or
a bioactive molecule can be used therapeutically to
kill or otherwise modify tumor cells.
~ hen the hybrid reagent described herein is
used in a phar~aceutical composition, it can be
administered by a wide variety of techniques. For
example, intravenously, parenterally, transdermally
subcutaneously or ~ia an implanted reservoir
containing the hybrid molecule. The form in which
the hybrid molecule will be administered (e.g.,
solution, emulsion) will depand on the route by
which it is administ0red. The quantity of the
hybrid molecule to be administered will be
determined on an indi~idual basis and will be based
at least in part on consideration of the
indi~idual's size, the severity of the symptoms to
be treated, and the result sought.
- :~, ...... , -.: .. -, . .. - . ,-, . , ... . :
,, . . . :: : . . :. ..
, , ., . . . : . , ,, ~,. :,.. , .,.,.. ,, ., , .: : : ,.:
.. ~ ' . ., . , ' .. :.: .: ,. : . . .: : ::
: . . , :, - , . : , : . , ., . . ~ .: :: .. :
WO91/12~23 PCT/US91/00971
2 ~ 7
-13-
This invention is further illustrated by the
following examples.
Exam~le 1 The Isolation of Anti Di~htheria Toxin
Antibodies Ca~able_of Releasin~ a
05 Molecule at a Selected ~H
~ice were im~unized with progressively increas-
ing doses of active diphtheria toxin (l ~g - 3 ~g
I.P.) or a high dose of formalin-inacti~ated
diphtheria toxoid (lOO ~g I.P.). Following a -~
booster injection of the immunogen, spleens were
re~oved and fused with NS-l cells to generate
hybridomas (Kohler and Milstein, Nature, 256:495
(1975)). Supern~tants fro~ microtiter wells with
clones were assayed for the ability to bind l25I-
diphtheria toxin using a polyethylene glycolprecipitation method. Antibody positive super-
natants usually bound 25,000 cpm while negatives and
controls bound only 4,000 cpm. In a typical fusion
approximately 35 positive clones were obtained from
the spleen of a single animal.
A second assay was developed in order to
examine the infl~ence of pH on the interaction
between dipheheria toxin and the different mono-
clonal antibodies. Diphtheria toxin (lO0 ~l at 300
~g/ml) was absorbet to polyvinyl microtiter wellsl
excell was washed off with PBS. Antibody (lO0 ~l at
1-50 ~g/ml) was then added, a}lowed to react for two
hours and the plate was washed with PBS. Attached
antibody was revealed by subsequent addition of a
l25I-goat antimouse IgG reagent (background was
: : -
.~
,
~:
, ',: : , . ' , , ' . , , ~ ' 1, ..
., . .: . , : . .. . : ' ' : ~
WO9l/1~023 PCT/~S~1/0097
~, r.~ ~
~ 14-
approximately lOO cpm, positive clones bound
approximately 1,000-3,000 cpm).
To test for pH eifects on toxin release, the
antibody ~as allowed to bind to the immobilized
05 diphtheria toxin for two hours in replicate wells
and then a small volu~e of concentrated buf~er was
added to provide a final pH of 7.0, 5.0 or 4.5.
Dissociation was allowed to proceed for different
time intervals (5-~0 minutes) at either 23C or 37C
lO (normal-body temperature). Released antibody was -~
quickly washed off the plates with PBS and the
a~ount re~aining was quantified using a 12 I-goat
antimouse IgG probe. This me~hod was used to
identify 23 clones producing antibody which rapidly
15 dissociated from diphtheria toxin at a pH o~ 4.5 and
eight clones having antibody that was sensitive to
release at a pH of 5Ø No release occurred at a pH
of 7.0,
The tima-course of dissociation at p~ 4.5 for
20 one of these monoclonal antibodies (D6B3) is shown
in Fi~ure 2. At 23C the rate of release was slower
and less co~plete than at 37C. Approximately 80
percent of the antibody initially bound dissociated
from diphtheria toxin and most of this occurred
25 within ~he iirs~ 5 ~inutes. It is known that the
diphtheria toxin ramains attached to the assay plate
since binding of monoclonal antibodies deri~ed irom
different clo~es remsined completely unaffected by
the same acid conditions.
Figure 3 shows that the bindin~ interaction of
this D6B3 antibody was much less sensitive to
. : , . . . :: ., . . .: :, .. ,.. :, : . .. . , , . . ::, :. .
WO91~12~23 PCT/US91/00971
29 t~i3~7
release at pH 5.0, with only 25 percent having
dissociated by 30 minutes in contrast to 80 percent
at pH 4.5 The kinetics of relçase for two
monoclonal antibodies which did dissociate ~t pH
05 5.~, at 37~C is shown in Figure 4. The binding
interaction between D5A7 snd diphtheria toxin was
even disrupted at pH levels as high as 5.5. Thus a
substantial fraotion of tiphtheria toxin was rapidly
relinquished by these different sntibodies at the
lO precise pH and temperat~re conditions fo~nd in ~-~
endosomal vesicles and other acidic compartments
within cells (Geisow, J.L. and W.H. Evans, Ex~. Cell
Res., 150:36-46-(1984))
___ _ ___
The pH-dependent break-up of antibody and toxin
was shown to be based upon conformational changes in
the toxin. Thus, the tl/2~1-2 min ior the acid
triggered dissociation of antibody and toxin is
close to the tl/2-30 sec for the pH induced
transition of free toxin ~Blewitt, M.G., et al.,
20 Biockem., 24:5458-5464 (1985)). Moreover, the D6B3
antibody bo~nd to formalin stabilized diphtheria ;~
toxoid at pH 7.0 but did not release when the pH was -
reduced to pH 4.5. Apparently the chemical
croqslinking of toxoid prevented the pH-induced
transition which allows D6B3 to dissociate from
native toxin.
Exam~le_2 Hybrid Me-iated-Delivery of
125I-Di~h~heria Toxln to Cells
~.______ ______________________
Hybrid antibodies were formed with various
30 anti-diphtheria toxin ~ntibodies by linking them to
,
.. . ..
. - . ~
" , , ~ ~,
WO91/12023 PCT/US91/00971
-16-
anti-transferrin receptor monoclonal antibodies by a
~ethod previously described (Raso, F., et al., NAT0
Advanced_Studies Institute, 82:119-138 (1984)~. The
dual specificity and cell targeting capability of
05 these hybrids was demonstrated using 125I-diphtheria
toxin (hereinafter 12 I-DT). CEM cells derived from
a patient with T-cell leukemia ~Foley, G.E., et al.,
Cancer, 18:522-529 (1965)), which have abundant
transferrin receptor on their surface, were used as
-10 a test line for anti-transferrin receptor/ anti- ~ -
diphtheria toxin hybrids and two different routes ~f
delivery were tested. The cells were either pre-
treated with the hybrid and washed so that the empty
toxin binding sites of surfsce-bound hybrids could
then capture subsequently added 125I-DT; or hybrid
plus 125I-DT were pre-complexed and then used as a
single agent for reaction with the cell surface
transferrin receptors.
CEM cells w~re incubated with the co~ponents
desi~nated in Table I for 30 minutes at 0 and then
washed with PBS to remo~e unbo~nd hybrid. They were
then exposed to 125I-DT for 30 minutes at 0, ~ashe~
with PBS and counted to measure the amount bound to
c~lls.
The results in Table I show that cells exposed
to an anti-trans~errin recaptor/anti-diphtheria
toxin hybrid (7D3/DlF3) bound ive times higher
levels o 125I-DT than untreated cells. This
enhanced binding was receptor-specific since pre-
occupying the tar e~ epitope using excess unmodi~ied
7D3 antibody blocked hybrid attach~ent and
,,
.' ':
WO91~12~3 PCT~USgl/Q097
subsequent l25I-DT binding (Table I). Hybrids
formed with different anti-diphtheria toxin
monoclonal antibodies (D4B7 and D5E8) showed si~ilar
toxin binding properties ~Table I).
05 TABLE_I
125
Binding of I-DT to Hybrid-Coated CEM Cells
- Pretreatment ~ - - CPM Bound
None 888
~D3/Dl~3 Hybrid 4,381
Excess 7D3 plus 7D3/DlF3 Hybrid973
..
None 556
7D3/D4B7 Hybrid 4,306
7D3/D5E8 Hybrid 5,657
CEM cells were treated for 1 hour at 0C with
an equivalent amount ofj l25I-~T either alone in PBS
or pre-comple~ed at 22D for 15' to hybrid at 10 8M
(Table II). Following treatment, the cells were
wa~hed ~ith PBS snd counted. Table II shows that
signifiGant delivery over ~he basal binding levels
was attained even though the concentration of
complex used to treat these cells was relatively low
(lO M).
... . , :
~ , : -
:. . ~ : -
W091/12023 PCT~US91tO0971
-18- :
TABLE_I I .
De1iVerY Of HYbr1d-COmP1eXed 125I-DT to CEM Cells
Treat~ent CPM Bound
I-DT slone 1,649
05 7D3/D4B7 Hybrid - 125I-DT co~plex 13,116
7D3~D5E8 Hybrid - 125I-DT complex 15,297
.. .. , :
Exam~le 3 Plate Assay for Dual Specificity of
HIV Directed Hybrids
An anei-HIV monoclonal antibody was elicited
using a synthetic envelope protein and used to form
the H~V-specific hybrid (anti-MIV/D5E8) by coupling
i~ to an anti-diphtheria toxin antibody (D5E8)
following a method previ~usly described (Raso, F.,
et al., NAT0 Advanced_Studies Inst$tute, 82:119-13B : :
(1984)). A solid-phase radioimmunoassay was devised
by adsorbing the envelope peptide antigen to the
wells of poly~inyl microtitre plates. PBS and
either antibody or hybrid at 6xlO 9M was then added
to the well for 2 hrs, and any unbound reagent was
washed off using PBS. The dual specificity of the
hybrid was demonstrated after allowing it to bind to
the coated pla~e via its ~IV-specific combinin~
;ites and then revealing its presence by binding
I~CRM107 to the free toxin-specific sites of the
composite molecule. Table III shows that the
anti-HIVjD5E8 hybrid bound 1251- CRM107 while
anti-HIV alone bound no toxin even though it was
:'
. . ..
::
~., , , . , . , - . ,
WO91~12~23 PCT/US91/~971
2~7~ 7
-19-
attached to the plate as evidenced by using an
5I-goat anti-mouse IgG probe.
TABLE~
Pl~te Assay to De~onstrate the Bindin~ of
05 Anti-HIV Antibody sind Hybrid
A~ount Bound (CPM)
~25I C~M107 125I G~M
PBS 307 253
anti-HIV 112 1,501
10 anti-~IV/D5E8 Hybrid 1,245
Example 4 H brid-Mediated Cytotoxicity of a Mutated
____ ____ _ ___ ___________ _ _______ ___.__________ ~
Form of Di~htheria Toxin
Tha availability of genetically or chemically
altered tiphtheria toxin cogeners (e.g., CRN107)
with no capacity for attachlng to cells pro~ides an
a~tded dimension to the hybrid delivery approach.
The cell-bindin~ defect ~hich makes these analogs :
non~- toxic to cells can be restored ~la the hybrid
carrier moiety so that its le~hal ~ction is aimed
exclusively at the selected cell sur~ace target.
Human mesothelioma cells (H-Meso) were used to
test the e~fectiveness of a~ti-transferrin receptor/
anti-diphtheria toxin hybrids (7D3/DlF3 and
7D3/D5E8) for restoring~the full cytotoxic potential
25 of CRM107. The~ H-meso cells were incubated for 2
hours at 37C with 4 x 10 8M CRM107 alone;
: .
C~ PCT/US91/0097
-20-
(4 x lO 8M) CRMl07 in co~binaeion with the hybrids
7~3/D5E8 or 7D3/DlF3 at 1 x lO M, or 4 x 10 M
CRMl07 in combination with the hybrids (1 x lO 8M)
plus excess ~nti-receptor antibody (7D3j (lO ~).
05 Cells were then pulse labeled with 3H-leucine for 30
min. ~-meso cells in media to which lOmM NH4Cl was
added were also incubated with the same components.
The data in Table IV show ~ha~ while CRMl07
alone was incapable of entering cells and inhibitin~
10 protein synthesis, it became-a ~ery-potent and - -
rapid-acting cytotoxin when used in combination with
the hybrid antibodies. This lethal action was
dependent upon hybrid-mediated delivery to trans-
ferrin receptors since little toxicity was obtained
when these sites were blocked by including an excess
of free anti-receptor antibody (7D3) during the 2
hour incubation time (Table IV).
The acid environment of intracellular compart-
ments is essential ~or c~ytotoxicity since this
induces the release of CRMl07 from the antibody and
translocation into the cytosol where it inactivates
elongation factor 2. This condition was demonstra-
ted by adding NH4Cl to the cells. This weak base,
which is known to raise vesicle pH, greatly reduced
the ability of the hybr~d-CRMlQ7 combination to kill
H-Meso cells (Table IV). The same experiments were
carried out usin& the anti-HIV/D5E8 hybrid ~2 x
lO ~M) plus CRMl07 (4 x 10 8M) using HIV-infected
. 8E5 cells as the ~arget (Folks, T.M., et al., J.
Ex~. ~ed., 164:280-290 (1986)). The s~e acid-
dependency was demonstrated (Table V).
:.
~ '
'' ' ~,
WO9l/120~3 PCT/US91/~0971
2~73~27
-21-
TABLE IV
Hybrid-Mediated Cytotoxic~ty of CRM107 Tested on Human
Mesothelioma Cells (2-hr Assay); Transferrin Receptor
Specificity and Acid-Dependency
05 3H-Leucine Incorporation Inhibition
___________(CP_?____ __ _(Pe~cent)
H-Meso Cells 92,560 --
, . _ . ... . . .. .
+CRM107 90,755 2
~7D3/D5E8 + CRM107 1,605 98
+7D3/DlF3 ~ CRM10' 8,050 91
+excess 7D3 + 7D3/D5E8 + CRM107 52,325 43 .
+excess 7D3 + 7D3~D1~3 + CRM107 53,960 42 . ;
.
H-Meso Cells + 10 mM NH4C1 92,435 --
+CRM107 76,8R5 17
~7D3/D5E8 + CRM107 52,105 44
+7D3/DlF3 + CRMI07 180,802 13
. -
,:
. ~, .
.
::
`
WO9l/12023 PCT/US91/00971
-22-
TABLE_V
: .
Acid-Dependency of Hybrid-Mediated Cytotoxicity of
CRM107 on HIV-Positive 8E5 Cells
3~-Leucine Incorporation Inhibition
05 (CPM) (percent)
.--..... HIV-Positive ~ 8E5 cells alone - 103,955
+CRM107 85,140 18
~NH4Cl + CRM107 82,115 21
~anti-HIV/D5E8 + CRM107 21,820 79
+NH4Cl + anti-HlVfDSE8 ~ CRM107 78,985 24
The transferrin receptor directed hybrid~
CRM107 complex was assayed on human colon adenocar-
cinoma cell~ to determine if the same high cytotoxic
potency found for the H-Meso and HIV-infected 8E5
cell lines extended to alternative malignant cell
typas. The combined action of CRM107 plus hybrid at
M produced extensive cell kill within two hours
~nd its potency was comparsble to 10 7~ native
.diphtheria~ toxin (Table VI). These results indicate
that hybrid-delivery not only renders C~M107
cytotoxic to cells but also suggests that its entry
via the trans~rrin pathway is as ef~icient as
tiphtheria toxin uptake by its usual mechanism.
Moreover, a transferrin/ D5E8 conjugate was .:
constructed to exa~ine~if ~ra,sferrin itself would
, .
WO91/12~23 PCT/US91/00971
~'7`~'~27
-23-
mediate delivery of CRM107 into cells. In fact,
this natural ligand coupled to the anti-diphtheria
toxin monoclonal antibody (D5E8) prcvided a slmilar
level of toxicity as the anti-transferrin receptor
05 (7D3) guided hybrid.
TABLE ~I
Lethal Effects of Anti-Transferrin Receptor Directed Hybrid
- - Plus CRM107 on Human Colon Adenocarcinoma Cells (2-hr. Assay)
3H-Leucine Inhibition
lO Incor~oration (CPM) (Percent)
_____ ___ ___ ___ _______ ,
LS174T cells 54,070 --
~CRM107 (10 7M) 48,3S5 11
+7D3/D5E8 (10 8~) + CRM107 (10 7M) 1,930 96
~Diphtheria Toxin (10 7N) 1,785 97
15 +Diphtheria Toxin (10 8M) 6,295 88
In addition to using ~he transferrin receptor
as a target for hybrid delivery, the common acute
lymphoblastic leukemia antigen (CALLA) was similarly
~asted as a site of entry into CALLA-bearing Nalm~l
leukemia cells (Raso, V., et al., Cancer Res.,
42:457-464 ~1982)). An anti-CALLA/D5E8 hybr~d was
formed and examined for its ability to kill thsse
cell~ in combination with CRM107 ollowing the
protocol set orth for H-meso cells and anti-trans-
ferrin receptor/anti-diphtheria toxin. However,
WO91/12023 PCT/US91/0097
-24-
incubation was carried out for 6 hours at the same
temper~ture (Table VII).
Good cell kill was achie~ed by targeting the
hybrid-C~M107 to this distinct membrane site;
05 however, the longer incubation time required
suggests that entry and/or release of toxin was
slower than for transferrin receptor directed
agents.
- TABLE VII
CALLA-Directed Cytotoxic Action of
Hybrid-CRM107 on Nalm 1 Cells (6-hr. Assay)
3H-Leucine Incorporated Inhibition
_ (CPM) (Percent~
Nalm-l Cells 22,130 ~-
+ anti-CALLA~D5E8 24,110 0
+ CRMl07 22r820 0
+ anti-CALLA/D5E8 ~ CRM107 4,080 82
Example 5 Kinet~cs of Cytotoxicit_ in H Meso Cells
O~e of the fundamental pre~ises underlyin~ the
acid-txiggered hybrid c~rrier concept predicts that
this mode of delivery will not 1nt~rfere with the
normal mechanism of toxin action after speciic
~ar~eting has been achieved. A critical measure of
toxin ef~iciency can be obtained by monitoring the
kinetic9 of inhlbition of protein synthesis, This
parameter accurately indicates how rapidly ~oxin
gains access to its tar~et in the cytosol (e.g.,
" .
.
`' '. ,.
- . .. .. - . , ., . , . . . . . . . ~ . . , . . - , . , . . , - . . - . - - - . . :
. , ,. , ~ , ., . ~ ;.
WO91/12023 PCT/US91/00971
2~7~2~
-25-
elongation factor 2) and was therefore used to
evaluate hybrid-dellvered CRM107 (Figure 5).
H-Meso cells were incubated at 37C for the
designated intervals with either 10 8M diphtheria
05 toxin, 10 M CRN107, or the anti-transferrin
receptor~anti-diphtheria toxin hybrid
(7h3/D3El)-CRM107 combination at 10 8M~ The cells
were then pulse labeled with 3H-leucine for 30
minutes to measure the exeent incorporation into
~ 10- protein co~pared to ~ntreated control cel-ls.---The- --
time course of protein synthesis inhibition as
reflected by 3H-let~cine incorporati~n, for H-Meso
cells incubated with 10 8M diptheria toxin alone,
10 8M CRM107 alone or wi~h the anti-transferrin
receptor/anti-diphtheria t~xin hybrid (7D3/D3El~
plus CRM107 at 10 8M was then measurad.
Figure 5 shows that both native toxin and the
CRM107 hybrid combination gave identical kinetics
profiles which were characterized by a 30-40 minute
lag period followed by a rapid inactivation phase
with tl/2 24 minutes and tl/2 - 26 minutes
respectively. Unbound CRM107 alone at 10 8M had no
effect on the abi}ity of the cells to synthesize
protein. The ~act that hybrid-delivered CRM107
killed cells as fast as natlve diphtheria toxin
su~gests that its release from the antibody
combining site was unimpeded and that there was no
intarruption of the normal course of events requirad
for its lethal action.
Finally, a co~alently-coupled anti-transferrin
receptor-CRM107 conjugate (7D3-CRM107) was
:
- .. .... - . : :. .. ..
WO9~/~2023 PCTJVS91/~971
-26-
constructed by standard disulfide-linkage methods
and its cytotoxic effect compared with the effect
produced by the 7D3/D5E8 hybrid plus CRM107.
Transferrin receptor positi~e CEM cells were
05 incubated for 16 hours at 37C with the designated
concentrations of the 7D3/D5E8 hybrid plus 10 7M
CRM107, the 7D3-CRM107 disulfid~-linked co~alent
conju~ate and nati~e diphtheria toxin, CRM107 alone
or 7D3JDSE8 hybrid alone. The cells ~ere then pulse
10--labeled wlth 3H-leucine for 30 minutes and the
amount of Incorporation into protein was compared
with untreated control cells.
Figure 6 shows the toxicity dose response
curves of the hybrid, the conjugate and native -
diphtheria to~in. The conjugate, 7D3-CRM107 was
cytotoxic to transferrin receptor positi~e cells,
the kinetics of cell killing was much slower than
that found for hybrid-deli~ered CRM107. CEM cells
are not particularly sensitive to diphtheria toxin
as reflected in the ID50 ~ 2 x lO 9M obtained with
native ~oxin. The transferrin-receptor directed
7D3-CRN107 conjugate was slightly ~ore effective,
gi~ing an ID50 ~ l x 10 9M. In contrast, hybrid-
delivered CRM107 (ID50 ~ 4 x lO 1 M) was 250-fold
more potent than the covalent con~ugate, based upon
the concentration of hybrid added. Neither the
7D3/D5E8 hybrid alone nor CRM107 alone had an effect
upon the cells. These results indicate that
covalent couplin~ can i~pede toxin action since the :
disulfide-llDked 7D3-CRN107 conju ate was slower
. ~ .
,
, ,", ,;,,, ,-" ,,,", ,,,, ,," ,,"",, " " "~,~" ~:
WO91~1~023 PCT/US91/00971
2~c~ ?~7
-27-
acting and less potent than the corresponding
7D3/D5E8 hybrid delivered CRNlO7.
Figure 7 shows dose response curves for
inhibition o protein synthesis in HIV-infected 8E5
05 cells after 16 hr exposure to CRMl07 plus hybrids
directed against either HIV or transferrin receptors
on the cell membrane. The ID50 for the
anti-HIV~DSE8 hybrid plus CRMl07 was 2xlO M but
ehis reagent became lO-ti~es more potent when nicked
10 -CRMl07- ~cleaved at a specific site using trypsin)- -
was used (ID50 - 2xlO lOM). It is believe~ that
proteolytic cleavage is a prerequisite for toxic
actlvity and normally occurs at the cell surface or
in sub.cellular compartments. This anti-HIV
hybrid-mediated cytotoxicity was blocked by
neutralizing intracellular compartments with NH4Cl
(Table V) and the uninfected control cell line w~s
Dot affected by hybrid-delivered CRMl07.
Equivalents
Those skilled in the art will know, or be able
to ascertain using no more than routine experi- :
mentation, many equivalents to the specific embodi-
ments of the ~nvention ~s described herein. These
and all other equiYalents are intended to be
encompassed by the followin~ claims.
